Gene Patents Struck Down by Court


This week, the court struck down the decision to let Myriad patent the BRCA1 and BRCA2 genes- the genes associated with hereditary breast and ovarian cancers. We received questions about what this decision means for people with cancer. Dr. Adam Clark, director of science and policy at the foundation, addresses those questions in the video below. Please feel free to leave any additional questions in the comments section. We will do our best to answer them directly.


  1. Andie says:

    Sounds like a slippery slope to me allowing human genes to be patented…

  2. Carol says:

    Does this also mean that other companies will be able to do genetic testing? As I understand it Myriad is the only company doing BRAC 1 and BRAC 2 testing worldwide (with agreements between other companies outside the US), which might explain the very high cost for this procedure. I live in Australia and while my test was covered by a government research program, I understand the cost is around $3,000.

Leave a Reply

Your email address will not be published. Required fields are marked *